<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643602</url>
  </required_header>
  <id_info>
    <org_study_id>NaBicTheo</org_study_id>
    <nct_id>NCT02643602</nct_id>
  </id_info>
  <brief_title>Does Bicarbonate in Addition to Theophylline Reduce CIN?</brief_title>
  <official_title>Does Bicarbonate in Addition to Theophylline Reduce Contrast Induced Nephropathy Compared to Sodium Chloride?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Contrast-induced nephropathy (CIN) is the third most frequent cause of hospital-acquired
      acute renal failure. Different regimes in the prophylaxis of CIN have been investigated in
      the last years. Recent Meta-analysis show a reduced incidence of CIN when theophylline is
      administered to the patients especially in patients with already existing renal impairment.
      Furthermore hydration with bicarbonate seems to to be superior to hydration with sodium
      chloride alone. The combination of the two prophylaxis has not been investigated yet.

      Aim of this prospective randomized trial is to investigate the effect of hydration with
      sodium bicarbonate compared to saline in addition to theophylline prophylaxis which all
      patients receive.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast induced nephropathy</measure>
    <time_frame>48 hours</time_frame>
    <description>Raise in serum creatinine of ≥25% or ≥0.5 mg/dl</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of serum creatinine levels over time</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of creatinine clearance over time</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pH</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood bicarbonate-concentration</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood sodium-concentration</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine pH</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine bicarbonate-concentration</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine pH sodium-concentration</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of patients with need for dialysis</measure>
    <time_frame>30 days</time_frame>
    <description>The patients medical record was reviewed to determine whether dialysis was performed within 30 days after contrast media application.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Radiographic Contrast Agent Nephropathy</condition>
  <arm_group>
    <arm_group_label>Bicarbonate and theophylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydration with bicarbonate in addition to theophylline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium and theophylline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydration with sodium chloride in addition to theophylline</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hydration with bicarbonate in addition to theophylline</intervention_name>
    <description>0.154-molar sodium bicarbonate; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours</description>
    <arm_group_label>Bicarbonate and theophylline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hydration with sodium chloride in addition to theophylline</intervention_name>
    <description>0.9% sodium chloride; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours</description>
    <arm_group_label>Sodium and theophylline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Increased risk for contrast induced nephropathy defined as:

          -  Serum creatinine level ≥ 1.1 mg/dl OR

          -  Serum creatinine level ≥ 0.8 mg/dl plus an additional risk factor like diabetes
             mellitus, renal failure in past medical history or nephrotoxic medication
             (aminoglycoside, vancomycin, amphotericin B, diuretic)

        Exclusion Criteria:

          -  pre-existing renal replacement therapy

          -  unstable serum creatinine levels (difference of more than ±0.4 mg/dl within 3 days
             before contrast application)

          -  contraindications for theophylline or sodium bicarbonate (allergies, tachycardia,
             alkalosis, hypokalemia)

          -  additional interventions that might influence renal function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Huber, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>2. Medizinische Klinik, Klinikum rechts der Isar der Technischen Universität München</affiliation>
  </overall_official>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

